Evidence map›Paper›PMID 41445729›Full record

SynthesisFrontiers in immunology2025

Gut microbiota metabolites in the immunoregulation of enteritis: research progress.

Shaochen Yu, Mengjie Zhang, Ziyue Dou, Beibei Tian, Jian Lu

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Gut microbiota and disease.Essays in biochemistry · 2026
    Article
  4. Review
  5. Review
  6. Structural-activity relationship ofFrontiers in immunology · 2026
    Review
  7. Review
  8. Review
  9. Review
  10. Dual immunomodulatory effects ofFrontiers in microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shaochen Yu *Department of Emergency and Critical Care Medicine, Chuzhou Integrated Traditional Chinese and Western Medicine Hospital, Chuzhou, Anhui, China.
Mengjie Zhang *Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Ziyue DouDepartment of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Beibei TianDepartment of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Jian LuDepartment of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The interaction between gut microbiota metabolites and the host immune system plays a crucial role in maintaining intestinal homeostasis and in the development of inflammatory bowel disease and other enteric conditions. This article presents a systematic review of the sources and functions of short-chain fatty acids, tryptophan metabolites, bile acids, and other microbial metabolites, focusing on how these metabolites regulate the function of immune cells, such as T cells, B cells, neutrophils, macrophages, and dendritic cells, as well as key inflammatory signaling pathways, including the NF-κB, NLRP3 inflammasome, and JAK-STAT pathways, thereby influencing intestinal barrier integrity. Also explored are potential therapeutic strategies based on microbial metabolites, including the application status and prospects of probiotic and prebiotic interventions, the direct administration of metabolites, and fecal microbiota transplantation. Although current research faces challenges such as unclear mechanisms, significant differences among individuals, and barriers to clinical translation, the development of multiomics technologies and precision medicine holds promise for providing more effective and personalized treatment strategies targeting gut microbiota metabolites for patients with enteritis.

Indexed as

EnteritisGastrointestinal MicrobiomeAnimalsBile Acids and SaltsFatty Acids, VolatileHumansImmunomodulationProbioticsBile Acids and SaltsFatty Acids, Volatilegut microbiota metabolitesimmunoregulationinflammatory bowel diseaseintestinal barriertherapeutic strategies

Identifiers

PMID41445729
PMCPMC12722823

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.